- Title
- Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.
- Creators
- NJ VogelzangTM BeerJ BartunkovaR KuklkK MillerWK OhS OudardHS PandhaAO SartorR SpisekNG BorgsteinWR Gerritsen
- Contributors
- AMER SOC CLINICAL ONCOLOGY (Publisher)
- Publication Details
- JOURNAL OF CLINICAL ONCOLOGY, Vol.33(15)
- Conference
- Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (Chicago, IL, 29/05/2015 - 02/06/2015)
- Date published
- 20/05/2015
- Date submitted
- 17/05/2017
- Identifiers
- 99511303902346
- Academic Unit
- University of Surrey
- Resource Type
- Conference presentation
Conference presentation
Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.
JOURNAL OF CLINICAL ONCOLOGY, Vol.33(15)
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (Chicago, IL, 29/05/2015 - 02/06/2015)
20/05/2015
Metrics
51 Record Views